2007–2012 · Founded
Abion was established with a focus on national R&D projects in the fields of protein, nucleic acid, and antibody therapeutics.
Company
A platform oncology company transitioning into Abion 2.0 — building the post-ADC era through iRAC, CLDN3, and introducing next-gen MET inhibition.
History
2013–2020 · Building the pipeline
Discovery and preclinical work established the c-MET, claudin-3 and interferon-β programs that make up today’s pipeline.
2021 · KOSDAQ listing
Listed on KOSDAQ under 203400, funding ABN401’s move into Phase 2 and the expansion of the antibody platform.
2022–2026 · Global validation
Phase 2 vabametkib data presented at ASCO, a licensing and co-development agreement for the claudin-3 antibody franchise, and iRAC preclinical data at AACR 2026.
Four modalities, one design principle
We pick the modality the target demands — small molecule, antibody, bispecific or antibody–cytokine fusion — and pair it with a diagnostic that identifies the patients likely to respond.
How we decide what to advance
Three things move a program forward: the biology is validated, the patient population can be identified, and a global partner can take it further.
Resistance-first biologyWe start where existing therapies fail: c-MET after EGFR-TKIs, and resistance to approved TROP2 ADCs.
Diagnostics from day oneCompanion diagnostics are developed alongside the drug, so the right patients are identified in trials and in clinic.
Built for partneringData, IP and regulatory strategy are prepared to global standards, ready for licensing or co-development.
Leadership
A scientist-led team with oncology, translational and regulatory experience across Korea, the US and Europe.
Young Khee Shin
CEO / CTO / Ph.D
Founder of Abion, leading its biomarker-based precision oncology strategy.
Sung Yoon Woo
Chief Financial Officer / CFA
Leads Abion´s financial strategy, capital raising, and long-term business planning.
Ki Ryong Jang
Chief Operating Officer
Oversees Abion´s operations and the foundation supporting its pipeline development.
Chan Kyu Lee
Chief Scientific Officer / Ph.D.
Leads Abion´s R&D Center, research strategy, and pipeline development.
